Extended Cox model for event-free survival in CR
| Covariate . | Coefficient estimate . | Effect . | P . |
|---|---|---|---|
| TA | 0.426 (0.144) | Negative | .003 |
| FAt | 0.558 (0.257) | Initially negative, then positive after about 1 y | .011 |
| FAt2 | − 0.347 (0.118) | ||
| Age | 0.011 (0.004) | Older age worse | .002 |
| Inv(16) or t(8;21) | − 0.641 (0.198) | Positive | .001 |
| Chromosome 5 and/or 7 abnormal | 0.803 (0.120) | Negative | < .001 |
| Treated in laminar air flow room | − 0.367 (0.116) | Positive | .002 |
| AHD present | 0.373 (0.113) | Negative | < .001 |
| Log platelet count | − 0.152 (0.049) | Higher better | .002 |
| Log WBC count | 0.106 (0.037) | Higher worse | .004 |
| Covariate . | Coefficient estimate . | Effect . | P . |
|---|---|---|---|
| TA | 0.426 (0.144) | Negative | .003 |
| FAt | 0.558 (0.257) | Initially negative, then positive after about 1 y | .011 |
| FAt2 | − 0.347 (0.118) | ||
| Age | 0.011 (0.004) | Older age worse | .002 |
| Inv(16) or t(8;21) | − 0.641 (0.198) | Positive | .001 |
| Chromosome 5 and/or 7 abnormal | 0.803 (0.120) | Negative | < .001 |
| Treated in laminar air flow room | − 0.367 (0.116) | Positive | .002 |
| AHD present | 0.373 (0.113) | Negative | < .001 |
| Log platelet count | − 0.152 (0.049) | Higher better | .002 |
| Log WBC count | 0.106 (0.037) | Higher worse | .004 |
CR, complete remission; TA, received topotecan + ara-C regimen; FA, received fludarabine + ara-C regimen; t, (weeks from CR)/20; AHD, antecedent hematologic disorder; WBC, white blood cell.
Other variables considered for inclusion in the final model with theP values obtained after adding each variable one at a time to the final model: performance status 3 or 4 (rather than 0-2)P = .09, percentage of marrow blasts P= .52, hemoglobin P = .10, log(bilirubin)P = .89, without either fludarabine or topotecan for treatment of newly diagnosed acute myeloid leukemia (rather than myelodysplasia) P = .69.